Engineered immune cells take aim at stubborn leukemia after transplant
NCT ID NCT07280494
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new treatment called CD7-targeted CAR-T cells for people with T-lymphoblastic leukemia or lymphoma that remains after a stem cell transplant. The therapy uses a patient's own or a donor's immune cells, modified to find and destroy cancer cells. The study will enroll 18 participants to check safety and how well it clears the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CD7-targeted CAR-T cells (a type of immune cell therapy)
What this could lead to
If successful, this could offer a new treatment option for patients with lingering leukemia or lymphoma after a stem cell transplant, potentially improving survival.
What could go wrong
This is a very early (Phase 1) and small trial (18 people), so safety and effectiveness are not yet proven. CAR-T therapy can cause severe side effects like cytokine release syndrome or graft-versus-host disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T LYMPHOBLASTIC LEUKEMIA/LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University People's Hospital
RECRUITINGBeijing, China, 100044, China
Contact Email: •••••@•••••